Detalhe da pesquisa
1.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617659
2.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Eur J Haematol
; 105(3): 286-291, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365249
3.
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Am J Hematol
; 88(10): 838-42, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23757199
4.
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Br J Haematol
; 176(4): 669-671, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26914729
5.
Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.
Am J Hematol
; 91(9): E353, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27194679
6.
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations.
Exp Hematol
; 34(12): 1680-6, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17157165
7.
Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts.
Mediterr J Hematol Infect Dis
; 12(1): e2020066, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32952977